Celldex Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2015 | — | $290.1M | $72.1M |
| FY2016 | — | $265.4M | $42.5M |
| FY2017 | — | $236.4M | $40.3M |
| FY2018 | — | $124.1M | $24.3M |
| FY2019 | — | $94.0M | $11.2M |
| FY2020 | — | $209.4M | $43.8M |
| FY2021 | — | $419.5M | $39.1M |
| FY2022 | — | $326.2M | $29.4M |
| FY2023 | — | $429.2M | $34.8M |
| FY2024 | — | $747.0M | $28.4M |